Academia can be an excellent source of novel drug targets and new technologies that can enhance medicinal discovery. Indeed, academic inventors or founders contributed to more than one-quarter of all medicines approved from 2001 through 2019.
Yet many sponsored research collaborations that hope to tap into academia fail. Academic-industry partnerships present a unique set of challenges that require thoughtful setup and dedicated execution from both the company and academic institution.
While there are many important details of a successful biopharma-academia collaboration, I see three key aspects that biopharma companies should take into account in order to increase the probability of a successful endeavor:
Create a display name to comment
This name will appear with your comment
